Navigation Links
LMS to delist from Amex
Date:5/1/2008

MONTREAL, May 1 /PRNewswire-FirstCall/ - LMS Medical Systems (TSX: LMZ, AMEX: LMZ), a healthcare technology company and developer of the CALM- patient safety software system for obstetrics, today announced that its Board of Directors has unanimously decided to delist the Company's common shares from Amex.

The decision is in keeping with the Company's previous announcement to streamline operations and control costs in order to become cash flow positive. It is expected that Amex trading will cease on or about May 22, 2008.

LMS common shares will continue to be traded on the Company's principal exchange, the TSX.

About LMS: LMS is a leader in the application of advanced mathematical modeling and neural networks for medical use. The LMS CALM Suite provides physicians, nursing staff, risk managers and hospital administrators with clinical information systems and risk management tools designed to improve outcomes and patient care for mothers and their infants during childbirth.

Except for historical information contained herein, the matters discussed in this news release are forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed implied by the forward-looking statements including, but without limitation, economic conditions in general and in the healthcare market, the demand for and market for our products in domestic and international markets, our current dependence on the CALM product suite, the challenges associated with developing new products and obtaining regulatory approvals if necessary, research and development activities, the uncertainty of acceptance of our products by the medical community, the lengthy sales cycle for our products, third party reimbursement, competition in our markets, including the potential introduction of competitive products by others, our dependence on our d
'/>"/>

SOURCE LMS MEDICAL SYSTEMS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Biotech delists shares from TSXV, continues OTCBB trading
2. XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
3. American Stock Exchange LLC to Delist Securities of AMS Health Sciences, Inc.
4. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
5. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
6. Barrs PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange
7. QMed, Inc. Receives NASDAQ Delisting Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...re inequalities may have the most significant impa...cancer (CRC) between African// Americans and Cauca...June 1, 2007 issue of CANCER, a peer-reviewed jour...is of data from published studies demonstrated tha...
... a handful of concerned citizens. Delhi, burning u...h Day Sunday, //by raising its voice on various is... are on the brink of a challenge,' said Ravi Aggar...GO. 'The issue of stopping deforestation and felli...
...ted with an electronic biometric attendance system...l be initially installed in a few primary schools,...state. It would first be installed in 15 schools o...f Dausa. 'Some of the machines have already reach...
...ion drive aimed at protecting millions of children...ealth experts, nearly 10% of the// children could ...f Health is conducting the MMR (measles, mumps and...will be on for two weeks. This is being funded by ...
Other Medicine News:Health News:Social Factors Not Genetics Drive Racial Disparities in Colorectal Cancer Survival 2Health News:Earth Day Celebrated With Hopes of a Greener Tomorrow 2
(Date:9/3/2008)...SELS, Belgium and GENEVA, Sept. 3 /- ...lestone in CHO based monoclonal antibody,productio...over 31 grams,per liter. This record level was acc...logies: (1) a high-performance stable Selexis CHO,... leading scientists at,Selexis SA using their prop...
(Date:9/3/2008)... Company to Discuss Phase 3 Plans with FDA...Therapeutics, Inc.,announced today that it succes...velopment of the company,s new, innovative low-dos...pany refers to by its internal product,code AG-200...sfully met its,primary endpoint of ovulation suppr...
(Date:9/3/2008)...509 to be Evaluated in Repeat-Dosing Study in Subj...ire-FirstCall/ -- Sangamo,BioSciences, Inc. (Nasda...ase,2 clinical trial (SB-509-801) to evaluate its ... degenerative motor-neuron disease for which there...amo,s drug, SB-509, is an injectable formulation o...
(Date:9/2/2008)...S, September 3 /-, - This ...ased the Risk,of Stroke by 34% in Patients With At...tely Treated by Antithrombotic Therapy, The resul...ENA study,were presented today at the clinical tri...ology congress 2008, in Munich, Germany. Previous ...
Breaking Medicine Technology:Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Amira Pharmaceuticals Appoints First Vice President of Development 5214 1Amira Pharmaceuticals Appoints First Vice President of Development 5214 2Agingcare com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 5211 1Agingcare com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 5211 2Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 1Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 2Sigma Aldrich Announces mirPremier 28TM 29 microRNA Isolation Kit for miRNA Purification 5208 3Spinal Stem Cells Offer Hope Against Back Pain 5205 1Spinal Stem Cells Offer Hope Against Back Pain 5205 2
...New Studies Confirm That Fusion Proteins Made by C...dies Demonstrate Increased,Anti-Tumor Activity Wit..., Calif., April 18, 2007,/PRNewswire-FirstCall/ --...e biopharmaceutical company developing targeted,mo...d hepatitis C,virus infection, today reported that...
...AITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2...edImmune, Inc. today,announced data from a preclin...rcinoembryonal antigen (CEA) were shown to prevent...etastases. An,established marker for tumor progres... and other human carcinomas. These data,presented...
Other Medicine Technology:Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 2Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 3Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 2Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 3Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 5
...ries Freezing Stages fit easily onto most microtom...arts and need only the AC supply and a trickle of ...ediately and can be maintained indefinitely. Stag...g temperatures can be set for different kinds of t...
ELISA kit for the quantitative determination of autoantibodies to glutamic acid decarboxylase (GAD65) in serum
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum
RIA kit for the quantitative determination of autoantibodies to insulin in serum
Medicine Products: